Wedbush Raises Earnings Projections for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) has received an update from equities researchers at Wedbush regarding its earnings estimates. On December 23rd, a research report indicated that Wedbush analyst L. Chico has revised the company's expected earnings for the first quarter of 2025. The new estimate anticipates earnings of $1.52 per share, which is an increase from the prior estimate of $1.49.

Analyst Ratings and Future Earnings Projections

In addition to the updated Q1 forecast, Wedbush has given an "Outperform" rating for Neurocrine Biosciences, setting a price target of $148.00 for the stock. The consensus estimate for the company's full-year earnings currently stands at $3.94 per share. Moreover, Wedbush provided projections for subsequent quarters: $1.82 EPS for Q2 2025, $1.90 EPS for Q3 2025, and $2.46 EPS for Q4 2025. For the full fiscal year 2025, earnings are expected to total $7.71 per share, with FY2026 estimates reaching $10.87 EPS.

Analysts’ Perspectives on Neurocrine Biosciences

Other financial analysts have also been assessing Neurocrine Biosciences. For instance, BMO Capital Markets lowered their price target on the stock from $128.00 to $114.00 while maintaining a "market perform" rating as of October 17th. Piper Sandler reaffirmed an "overweight" rating with a higher price target of $160.00 for Neurocrine Biosciences. Similarly, StockNews.com downgraded the stock from a "strong-buy" to a "buy" rating at the beginning of November. Needham & Company LLC issued a “hold” rating on December 20th, while Royal Bank of Canada knocked their price target down from $136.00 to $133.00.

Overview of Current Stock Ratings

Among analysts that have followed Neurocrine Biosciences, five have assigned a hold rating, eighteen have rated it as a buy, and one has given a strong buy rating. According to data from MarketBeat, the stock boasts a consensus rating of “Moderate Buy” and a target price of $166.29.

Neurocrine Biosciences Stock Performance

On Tuesday, shares of Neurocrine Biosciences opened at $136.53. The company has a market capitalization of $13.82 billion, a P/E ratio of 36.60, and a beta of 0.34. Over the last 50 days, the average price of the stock has been $124.40, and the 200-day moving average price is $130.59. Notably, Neurocrine has seen a 12-month low of $110.95 and a high of $157.98.

Insider Activity and Institutional Investments

In recent insider trading news, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences on December 17th at an average price of $135.00, totaling $147,285. Following this sale, she retained 2,507 shares, now valued at approximately $338,445. Another insider, Jude Onyia, sold 2,331 shares on November 29th at an average price of $126.29, representing a total of $294,381.99. Following this transaction, he owns 15,449 shares valued at about $1,951,054. Insider ownership stands at 4.30% of the company’s stock.

On the institutional front, several investors have either increased or decreased their holdings in Neurocrine Biosciences. Ashton Thomas Private Wealth LLC initiated a new position valued at $28,000, while Innealta Capital LLC invested $30,000 during the same period. Blue Trust Inc. increased its stake by 171.9%, now holding 348 shares valued at around $40,000. Plato Investment Management grew its position by 44.1%, owning 425 shares worth $59,000. Truvestments Capital acquired shares worth about $63,000 in a new investment. Notably, institutional investors and hedge funds collectively own 92.59% of Neurocrine Biosciences’ stock.

Company Overview

Neurocrine Biosciences, Inc. is engaged in the discovery, development, and marketing of pharmaceuticals specifically targeting neurological, neuroendocrine, and neuropsychiatric disorders. Their product lineup includes INGREZZA for treating tardive dyskinesia, ALKINDI for adrenal insufficiency, and Efmody for classic congenital adrenal hyperplasia, among others.

Neurocrine, Earnings, Wedbush